Dr. Alo says the heart benefit isn't just a byproduct of weight loss. That's his view, posted on social, not a new study.
Recap by typeshit. Post by @dr.alo on Instagram.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
3:21
A short upload with no description, so the reasoning behind the claim isn't given. Worth a tap only if you follow the gray market retatrutide talk.
Researchers found the peptide they built as a treatment already circulates in human blood, at lower levels in people with cognitive impairment.
Loading…